<span item_type="fundamental" item_id="6667c3fc8472da8c7ca1479a6f8c1a54" counter_id="ST/US/XOMAO" env="prod"></span><span item_type="announcement" item_id="581946250981804673" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 9.351 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.7.</p><p></p><h3>Segment Revenue</h3><ul><li>XOMA Royalty received $43.9 million in royalties and milestones from its partners in the first nine months of 2025, including $14.3 million from royalties during the third quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared to $7.2 million and $19.8 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li>R&amp;D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li>G&amp;A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively, compared to $8.0 million and $27.5 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li>Net income for the three and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash provided by operating activities was $8.4 million for the nine months ended September 30, 2025, compared to - $10.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li><li>Cash, cash equivalents, and restricted cash at the end of the period were $130.6 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Gains on acquisitions in the third quarter of 2025 were $17.9 million for HilleVax and $1.8 million for Turnstone.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>XOMA Royalty anticipates several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape its business trajectory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span> The company aims to become a self-sustaining entity from royalties alone over the near term.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span> Forward-looking statements include potential commercial payments and developments related to various assets in XOMA Royalty’s portfolio.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525275971/d35634dex991.htm"></span></li></ul>

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 8-K: FY2025 Q3 Revenue: USD 9.351 M